Investigational treatments of venous thromboembolism

Bibliography

• ANDERSON FA Jr, SPENCER FA: Risk factors for venous thromboembolism. Circulation (2003) 107(23 Suppl. 1):I9-I16.
   PubMed Web of Science ®Google Scholar
• KEARON C: Natural history of venous thromboembolism. Circulation (2003) 107(23 Suppl. 1):I22-I30.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, LEVINE MN, HIRSH J et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. (1995) 332(20):1330-1335.
   PubMed Web of Science ®Google Scholar
• SPYROPOULOS AC: Managing oral anticoagulation requires expert experience and clinical evidence. J. Thromb. Thrombolysis (2006) 21(1):91-94.
   Google Scholar
• BATES SM, GINSBERG JS: Anticoagulants in pregnancy: fetal effects. Baillieres Clin. Obstet. Gynaecol. (1997) 11(3):479-488.
   PubMedGoogle Scholar
• HUTTEN BA, PRINS MH, GENT M, GINSBERG J, TIJSSEN JG, BULLER HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. (2000) 18(17):3078-3083.
   Google Scholar
• PALARETI G, LEGNANI C, LEE A et al.: A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. (2000) 84(5):805-810.
   Google Scholar
• GREER IA, NELSON-PIERCY C: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood (2005) 106(2):401-407.
   PubMed Web of Science ®Google Scholar
• LEE AY, LEVINE MN, BAKER RI et al.: Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. (2003) 349(2):146-153.
   PubMed Web of Science ®Google Scholar
• BATES SM, GREER IA, HIRSH J, GINSBERG JS: Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(Suppl. 3):627S-644S.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, HIRSH J, SAMAMA MM: New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(Suppl. 3):265S-286S.
   PubMed Web of Science ®Google Scholar
• DAHL OE: Mechanisms of hypercoagulability. Thromb. Haemost. (1999) 82(2):902-906.
   Google Scholar
• FERNANDEZ PM, PATIERNO SR, RICKLES FR: Tissue factor and fibrin in tumor angiogenesis. Semin. Thromb. Hemost. (2004) 30(1):31-44.
   Google Scholar
• GIRARD TJ, NICHOLSON NS: The role of tissue factor/Factor VIIa in the pathophysiology of acute thrombotic formation. Curr. Opin. Pharmacol. (2001) 1(2):159-163.
   Google Scholar
• WEITZ JI, BATES SM: New anticoagulants: J. Thromb. Haemost. (2005) 3(8):1843-1853.
   Google Scholar
• HIRSH J, O'DONNELL M, WEITZ JI: New anticoagulants. Blood (2005) 105(2):453-463.
   PubMed Web of Science ®Google Scholar
• LEE A, AGNELLI G, BULLER H et al.: Dose–response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation (2001) 104(1):74-78.
   PubMed Web of Science ®Google Scholar
• BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78(1):471-477.
   Google Scholar
• SANDSET PM, ABILDGAARD U, LARSEN ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res. (1988) 50(6):803-813.
   PubMed Web of Science ®Google Scholar
• BIEMOND BJ, FRIEDERICH PW, LEVI M, VLASUK GP, BULLER HR, TEN CATE JW: Comparison of sustained antithrombotic effects of inhibitors of thrombin and Factor Xa in experimental thrombosis. Circulation (1996) 93(1):153-160.
   PubMed Web of Science ®Google Scholar
• BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. (2003) 349(18):1695-1702.
   PubMed Web of Science ®Google Scholar
• BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. (2004) 140(11):867-873.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, HERAULT JP, BERNAT A et al.: Chemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91(11):4197-4205.
   PubMed Web of Science ®Google Scholar
• REITER M, BUCEK RA, KOCA N, HEGER J, MINAR E: PERSIST: idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinolysis (2003) 14(1):61-65.
   Web of Science ®Google Scholar
• BULLER HR ON BEHALF OF THE VAN GOGH INVESTIGATORS: Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep-vein thrombosis or pulmonary embolism – the Van Gogh Investigators. Blood (2006) 108(11):6a.
   Web of Science ®Google Scholar
• BULLER HR ON BEHALF OF THE VAN GOGH INVESTIGATORS: Once weekly subcutaneous idraparinux versus placebo in the extended treatment of deep-vein thrombosis or pulmonary embolism – the Van Gogh Investigators. Blood (2006) 108(11):172a.
   Google Scholar
• ALEXANDER JH, DYKE CK, YANG H et al.: Initial experience with Factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J. Thromb. Haemost. (2004) 2(2):234-241.
   Google Scholar
• ALEXANDER JH, YANG H, BECKER RC et al.; XaNADU-ACS INVESTIGATORS: First experience with direct, selective Factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J. Thromb. Haemost. (2005) 3(3):439-447.
   Google Scholar
• LASSEN MR, DAVIDSON BL, GALLUS A, PINEO G, ANSELL J, DEITCHMAN D: A Phase II randomized, double-blind, five-arm, parallel-group, dose–response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood (2003) 102:15a.
   Web of Science ®Google Scholar
• LUETTGEN JM, BOZARTH TA, BOZARTH JM et al.: In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable Factor Xa inhibitor. Blood (2006) 108(11):112b.
   Google Scholar
• WEITZ JI: Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Haemost. (2006) 96(3):274-284.
   Google Scholar
• PERZBORN E, STRASSBURGER J, WILMEN A et al.: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. (2005) 3(3):514-521.
   Google Scholar
• KUBITZA D, BECKA M, VOITH B, ZUEHLSDORF M, WENSING G: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin. Pharmacol. Ther. (2005) 78(4):412-421.
   Google Scholar
• TURPIE AG, FISHER WD, BAUER KA et al.; ODIXA-KNEE STUDY GROUP: BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A Phase II dose-ranging study. J. Thromb. Haemost. (2005) 3(11):2479-2486.
   Google Scholar
• ERIKSSON BI, BORRIS L, DAHL OE et al.; ODIXA-HIP STUDY INVESTIGATORS: Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. (2006) 4(1):121-128.
   Google Scholar
• ERIKSSON BI, BORRIS L, DAHL OE et al.; ODIXA-HIP STUDY INVESTIGATORS: A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 14(22):2374-2381.
   Web of Science ®Google Scholar
• BULLER HR ON BEHALF OF THE EINSTEIN-DVT STUDY GROUP: Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study. Eur. Heart J. (2006) 27(Suppl. 1):761.
   Google Scholar
• AGNELLI G, GALLUS A, GOLDHABER S et al.: Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) – the ODIXa-DVT dose-ranging study. Eur. Heart J. (2006) 27(1 Suppl.):761-762.
   Google Scholar
• ERIKSSON BI, TURPIE AGG, LASSEN MR et al.: YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood (2005) 106(11):530a-531a.
   Google Scholar
• FUKUDA F, HONDA Y, MATSUMOTO C et al.: Impact of antithrombin deficiency on efficiencies of DU-176b, a novel orally active direct Factor Xa inhibitor, and antithrombin dependent anticoagulants, fondaparinux, and heparin. Blood (2005) 106(11):533a.
   Google Scholar
• AGNELLI G, HAAS SK, KRUEGER KA, BEDDING AW, BRANDT JT: A Phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood (2005) 106(11):85a.
   Google Scholar
• ROTHLEIN R, SHEN JM, NASER N et al.: TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A/V shunt models without prolonged bleeding. Blood (2005) 106(11):535a-536a.
   Google Scholar
• LUNDBLAD RL, BRADSHAW RA, GABRIEL D, ORTEL TL, LAWSON J, MANN KG: A review of the therapeutic uses of thrombin. Thromb. Haemost. (2004) 91(5):851-860.
   Google Scholar
• BAUGHMAN RA, KAPOOR SC, AGARWAL RK, KISICKI J, CATELLA-LAWSON F, FITZGERALD GA: Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation (1998) 98(16):1610-1605.
   PubMed Web of Science ®Google Scholar
• HULL RD, KAKKAR AK, MARDER VJ, PINEO GF, GOLDBERG MM, RASKOB GE; PROTECT trial: oral SNAC–heparin vs enoxaparin for preventing venous thromboembolism following total hip replacement. Blood (2001) 100(11):148a-149a.
   Web of Science ®Google Scholar
• KELTON JG: The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest (2005) 127(Suppl. 2):9S-20S.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, HUDOBA M, MASSEL D, MARAGANORE J, HIRSH J: Clot-bound thrombin is protected from inhibition by heparin–antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. (1990) 86(2):385-391.
   Google Scholar
• MATTSSON C, MENSCHIK-LUNDIN A, NYLANDER S, GYZANDER E, DEINUM J: Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thromb. Res. (2001) 104(6):475-486.
   PubMed Web of Science ®Google Scholar
• FRANCIS CW, DAVIDSON BL, BERKOWITZ SD et al.: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. (2002) 137(8):648-655.
   PubMed Web of Science ®Google Scholar
• FRANCIS CW, BERKOWITZ SD, COMP PC et al.; EXULT A STUDY GROUP: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. (2003) 349(18):1703-1712.
   PubMed Web of Science ®Google Scholar
• SCHULMAN S, WAHLANDER K, LUNDSTROM T, CLASON SB, ERIKSSON H; THRIVE III INVESTIGATORS: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. (2003) 349(18):1713-1721.
   PubMed Web of Science ®Google Scholar
• FIESSINGER JN, HUISMAN MV, DAVIDSON BL et al.; THRIVE TREATMENT STUDY INVESTIGATORS: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 293(6):681-689.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, AGNELLI G, COHEN AT et al.; EXPRESS STUDY GROUP: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. (2003) 1(12):2490-2496.
   Google Scholar
• ERIKSSON BI, AGNELLI G, COHEN AT et al.; METHRO III STUDY GROUP: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb. Haemost. (2003) 89(2):288-296.
   Google Scholar
• STANGIER J, RATHGEN K, GANSSER D, KOHLBRENNER V, STASSEN JM: Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers. Thromb. Haemost. (2001) 86:OC2347 (Abstract).
   Google Scholar
• ERIKSSON BI, DAHL OE, BULLER HR et al.; BISTRO II STUDY GROUP: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. (2005) 3(1):103-111.
   Google Scholar
• COOMBE S, ALLEN G, KENNEDY A: A Phase I double-blind, ascending dose study of an oral synthetic direct thrombin inhibitor, TGN167. Blood (2005) 106(11):530a.
   Google Scholar
• BULLER HR, SOHNE M, MIDDELDORP S: Treatment of venous thromboembolism. J. Thromb. Haemost. (2005) 3(8):1554-1560.
   Google Scholar